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Abbreviations
aa amino acid
Ang angiopoietin
BEC blood vascular endothelial cell
E. embryonic day
EC endothelial cell
ECM extracellular matrix
Flk-1 fetal liver kinase 1 (mouse VEGFR-2)
Flt-1 fms-like tyrosine kinase-1 (VEGFR-1)
Flt-4 fms-like tyrosine kinase-4 (VEGFR-3)
Ig immunoglobulin
kD kilodalton
KDR kinase insert domain containing receptor (human VEGFR-2)
KS Kaposi’s sarcoma
LEC lymphatic endothelial cell
LYVE-1 lymphatic vessel endothelial hyaluronan receptor -1
MoAb monoclonal antibody
mRNA messenger ribonucleid acid
NRP neuropilin
P. postnatal day
PoAb polyclonal antibody
PECAM-1 platelet endothelial cell adhesion molecule-1
PDGF platelet-derived growth factor
PDGFR PDGF receptor
PlGF placenta growth factor
RTK receptor tyrosine kinase
SMC smooth muscle cell
Tek tunica interna endothelial cell kinase (Tie-2)
Tie tyrosine kinase with Ig and EGF homology domains (Tie-1)
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
VWF von Willebrand factor
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Abstract
Blood and lymphatic vessels develop in a
parallel, but independent manner, and
together form the circulatory system allowing
the passage of fluid and delivering molecules
within the body. Although the lymphatic
vessels were discovered 300 years ago, at the
same time as the blood circulation was
described, the lymphatic system has remained
relatively neglected until the present. This is
in part due to the difficulties in recognizing
these vessels in tissues because of a lack of
specific markers. Over the past few years
several molecules expressed specifically in the
lymphatic endothelial cells have been
characterized, and knowledge about the
lymphatic system has started to accumulate
again.
The VEGF (Vascular Endothelial Growth
Factor) family of growth factors and receptors
is involved in the development and growth of
the vascular endothelial system. Two of its
family members, VEGF-C and VEGF-D regulate
lymphatic endothelial cells via their receptor
VEGFR-3. These are the first molecules found
to be involved in the biology of the lymphatic
vessels, and their discovery has opened new
lines of inquiry in the study of lymphatic
endothelial cell regulation. The role of the
lymphatic vessels in immune responses and
certain pathological conditions can be studied
in more detail as the blood and lymphatic
vessels seem to be involved in many diseases
in a coordinated manner. Discoveries made so
far will be helpful in the diagnosis of certain
vascular tumors, in the design of specific
treatments for lymphedema, and in the
efforts to prevent the metastatic tumor
spread via the lymphatic system.
The present study was undertaken to
characterize the biological role of growth
factors VEGF-C and VEGF-D and their receptor
VEGFR-3. VEGFR-3 is shown to have an
important role in the embryonic development
of the cardiovascular system, before the
lymphatic vessels start to form. In adults the
expression of VEGFR-3 is mainly restricted to
lymphatic endothelial cells, where it serves as
a molecular marker for these vessels. In
experimental models, VEGF-C and VEGF-D are
shown to induce the growth of new lymphatic
vessels via VEGFR-3 and this process is also
shown to be a critical step in the metastatic
processes of the tumor cells.
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Review of the literature
Blood vessel development
The oxygen and nutrients supplied by the
vascular system are crucial for cell function
and survival. The cardiovascular system is the
first organ system to develop in embryos, as it
supplies oxygen and nutrients to the growing
tissues. During organogenesis, the proximity of
growing cells to the circulation is ensured by
the coordinated growth of blood vessels and
organ parenchyma. Embryonic vascular
development involves a complex series of
events during which the endothelial cells
differentiate, proliferate, migrate and
undergo maturation into an organized network
of vessels (158, 159). The first step in the
development of the blood vessels is called
vasculogenesis, in which endothelial cells are
generated from their mesenchymal precursors
and spontaneously assemble into tubules that
fuse to form the primary vascular plexus of
the embryo. Remodelling and expansion of
these primary vessels into arteries, veins and
capillaries of different sizes is called
angiogenesis (Fig. 1). In the yolk sac blood
islands, mesenchymal cells give rise to both
endothelial and hematopoietic cells (30).
These cells organize into clusters consisting of
future endothelial cells in the outer layer
surrounding the inner hematopoietic cells.
The endothelial cells then coalesce with those
of the neighboring blood islands to form a
primitive honeycomb-like blood vessel
network, and the hematopoietic cells
differentiate into erythrocytes.
A complex orchestration of molecular
regulators is needed for the blood vessels to
grow. Sprouting of new vessels from pre-
existing ones is the most frequent mechanism
of angiogenesis in embryos, and it involves
several sequential steps (199). The
extracellular matrix components are degraded
locally by proteases produced by the
endothelial cells. This allows the chemotactic
migration of endothelial cells towards
angiogenic stimuli. The endothelial cells
proliferate   and    form       loops,     which
become perfused with circulating blood. The
loops between the vessels can also form by
another mechanism called intussusceptive
growth, a form of angiogenesis involving the in
situ remodelling of the vessels by protruding
interstitial tissue columns. In this process a
large sinusoidal capillary can be divided into
smaller capillaries, which then grow
separately (158).
While endothelial cells initiate angiogenesis,
they cannot complete the process. Newly
formed capillary sprouts are fragile and
remain susceptible to remodelling as long as
they lack appropriate perivascular structures.
The maturation of new blood vessels into
stable and functional vessels requires the
accumulation of a basal lamina and
recruitment of pericytes and smooth muscle
cells to cover tightly the abluminal side of the
vessel (80). The smooth muscle cells provide
structural support to the larger vessels and
are important regulators of blood flow and
pressure by their contractile abilities.
The vascular system is a highly heterogeneous
and non-uniform organ system (64, 195, 205).
Endothelial cells differ considerably in the
arterial, capillary and venous compartments
and there is further heterogeneity between
the different organs (39). Recent molecular
probing of the endothelial cell surface by
phage display library panning in vivo has
revealed striking molecular specificity for the
availability of molecular determinants in
different vascular endothelia (164).
Endothelial cells in different vessels also have
distinct characteristics, such as fenestrations,
cell junctions, enzymes and carrier systems.
Differentiation of endothelial cells is
dependent on interactions with local
parenchymal cells in the target tissues.
Although it is not always known which factors
induce the organotypic differentiation of
endothelial cells, the existence of such cell-
cell interactions seems to be widely accepted.
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Figure 1. Embryonic blood vessel development. Endothelial precursors, angioblasts,
assemble into a primitive network of vessels, which further expand and remodel to form
circulatory system. Perivascular structures cover and stabilize the mature vessels.
Adapted from Carmeliet (30).
Physiological and pathological
angiogenesis
Angiogenesis is also required for the
maintenance of the functional and structural
integrity of tissues during post-natal life.
Vasculogenesis is probably restricted to early
development, while new vessels in adults
appear to be formed by angiogenesis (30).
However, adults are apparently able to
mobilize bone marrow-derived endothelial
precursor cells for angiogenesis (156). In
healthy adults the endothelial cell turnover is
usually very low and the vascular endothelia is
maintained in quiescence by a balance of
positive and negative regulators of
angiogenesis. Angiogenesis is limited to sites
where the metabolic demands of the tissue
are such that new blood vessels are needed.
Cells suffering from hypoxia start to release
angiogenic factors in order to establish better
contact with the circulating blood. In wound
healing, fracture repair, inflammation,
folliculogenesis and ovulation during the
menstrual cycle, as well as in situations of
ischemia, the positive regulators predominate,
leading to the activation of angiogenic
mechanisms (59).
In contrast to developmental angiogenesis,
angiogenesis in adults originates mostly in
mature blood vessels. In embryos endothelial
cells are loosely connected and actively
growing, whereas in adults they are quiescent
and encapsulated by a thick mural coat.
Therefore the blood vessels must first become
destabilized to allow new growth. In contrast
to angiogenesis in embryos, there is often
inflammation associated with adult
a n g i o g e n e s i s ,  a t t r a c t i n g
monocytes/macrophages, platelets, mast cells
and other leukocytes. Angiogenesis results in a
higher capillary density, but also the larger
vessels are modified by the lack of an
adequate oxygen supply. In the case of acute
or chronic occlusion of a major artery
(coronary, femoral artery), preexisting
arteriolar connections can be recruited to
bypass the site of occlusion. Arteriogenesis
produces rapid growth of the preexisting
collateral vessels, which are not perfused with
blood under normal flow conditions. These
vessels have the ability to dramatically
                                                                    VEGFR-3 in Angiogenesis and Lymphangiogenesis    7
increase their lumen by proliferation of
endothelial and smooth muscle cells (26).
One of the most extensively studied forms of
pathological angiogenesis is tumor
angiogenesis (58). Like normal cells, tumor
cells need to be located at a close distance
from the blood vessels serving the metabolic
demands of the growing tumor. The stage in
tumor development, when a solid tumor grows
beyond a few millimeters in diameter and
starts to generate its own microcirculation is
called the angiogenic switch (60).  It means
the transition of an avascular tumor to a
tumor with its own blood supply. At this stage
the endothelial cells transit from a quiescent
into an angiogenic state. The positive
regulators are induced and negative regulators
often decrease. Tumor blood vessels are leaky
and immature, at least partly because the
pericytes and smooth muscle cells are usually
poorly recruited to the tumors (58).  These
vessels resemble angiogenic vessels in other
settings, such as in wound healing, with the
exception that tumor vessels do not mature
properly and some of the endothelial cells in
the tumor vessels are replaced by tumor cells
(35). Angiogenesis also takes place in other
pathological conditions such as proliferative
retinopathy, rheumatoid arthritis, psoriasis
and juvenile hemangioma (59).
Lymphangiogenesis
Lymphatic vessels are also part of the vascular
circulatory system. The lymphatic system
comprises of an extensive network of
capillaries, collecting vessels and ducts that
permeates most of the organs (165). Unlike
the blood vasculature, which forms a
continuous loop, the lymphatic system is an
open ended, one-way transit system. It assists
in maintaining the blood volume, carries cells,
interstitial fluid components and metabolites
that leak from the capillaries and returns
them to the venous circulation via the
thoracic duct.
The lymphatic vessels also form part of the
immune system by continuously circulating the
white blood cells within the lymphoid organs
(spleen, tonsils, thymus, Peyer patches and
lymph nodes) and bone marrow and
transporting antigen-presenting cells.
Mononuclear phagocytes and also lymphocytes
patrolling the tissues enter the afferent lymph
vessels and the lymph nodes to elicit primary
immune responses before re-entering the
vasculature. Endothelial receptors and binding
proteins are involved in this trafficking of
specific lymphatic cell populations.
Lymphatic vessels start to develop in embryos
around midgestation, in parallel with the
development of blood vessels and most of the
organs. When the embryo grows, these vessels
are needed for the regulation of the
interstitial tissue pressure. The origin of the
lymphatic vessels has long been controversial.
Historically, the best accepted view of
lymphatic development is the one proposed by
Sabin (166, 167). Sabin proposed that early in
fetal development, isolated primitive lymph
sacs originate by endothelial cell budding from
embryonic veins. Sabin’s model proposes that
the peripherial lymphatic system then spreads
from these primary lymph sacs by endothelial
sprouting into the surrounding tissues and
organs where local lymphatic capillaries form.
An alternative model has suggested that the
initial lymph sacs arise in the mesenchyme
from precursor cells independent of the veins
and secondarily establish venous connections
(85). Although recent reports about the
development of the lymphatic vessels support
Sabin’s theory (44, 198), the existence of
primitive lymphangioblasts, which can be
recruited by the developing lymphatic vessels
has been shown at least in avian species (171).
One should thus note, that a combination of
the two mechanisms is possible, whereby
centrifugally sprouting lymphatic vessels
anastomose with lymphatics developing from
lymphangioblasts in tissues.
The lymphatic vessels differ in many ways
from the blood vessels, but they also share
many properties. Both vascular systems are
lined by the endothelium and the larger
vessels are supported by a smooth muscle
framework, particularly around luminal
valves, which are present in the veins and in
the large lymphatics (203). The smooth muscle
layer in blood vessels controls the contractile
tone of the vessels in response to vasoactive
substances. Blood vessels have a continuos or
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fenestrated basement membrane and tight
interendothelial junctions, which make the
vessel wall selectively permeable to cells,
fluids and molecules, whereas lymphatic
vessels have a relatively free import for
interstitial fluid. Lymphatic endothelial cells
have complex overlapping intercellular
junctions and specialized anchoring filaments,
which hold the vessel open as tissue pressure
rises (203). It has been suggested that these
properties provide the lymphatics with a
second valvular function (189).  Liquid,
macromolecules and migrating cells pass
through the blood capillary endothelia, enter
the tissues and are gradually absorbed into
the lymphatic system. The fluid is transported
via the lymphatic capillaries into the
collecting vessels and through the lymph
nodes, returning eventually to the circulation.
           
Figure 2. Structure of the blood (left) and lymphatic (right) capillaries. Lymphatic
vessels resemble blood vessels but are thinner-walled and more irregular and allow
relatively free import of interstitial fluid and macromolecules. Blood vessels are
supported by the perivascular smooth muscle cells whereas typical for the lymphatic
vessels are specific anchoring filaments (af), which attach the vessels to the surrounding
tissue.
Molecular regulation of blood and
lymphatic vessels
Intercellular signalling mechanisms which
govern the formation of blood and lymphatic
vessels have emerged relatively recently. The
complexity of endothelial cells indicates that
its regulation must involve many
developmental  and t i s sue-speci f ic
differentiation factors. Angiogenic signals are
mediated by a number of growth factors and
cytokines, and the balance between the
positive and negative regulators maintains the
adult vessels in a quiescent state (reviewed in
(76)). Whenever the balance is disturbed the
vessels react either by activating the
angiogenic responses or regress by apoptosis
when sufficient growth signals are not
present. Interaction of angiogenic growth
factors with their target cells triggers a
cascade leading to the formation of blood
vessels. Less is known about the regulation of
the lymphatic vessels, although similar
mechanisms seem to be involved.
Blood vessel development depends on
members of the Vascular Endothelial Growth
Factor (VEGF) family of proteins. This family
consist of VEGF, VEGF-B, VEGF-C, VEGF-D,
VEGF-E and PlGF (placenta growth factor),
which bind and activate cell surface receptors
and regulate endothelial cell growth and
differentiation (Fig.3) (96). The VEGFR family
includes VEGFR-1 (also known as Flt-1),
VEGFR-2 (Flk-1 / KDR) and VEGFR-3 (Flt-4)
tyrosine kinase receptors. Neuropilins 1 and 2
(NRP-1/-2) are another class of high affinity
non-tyrosine kinase receptors for VEGFs on
endothelial and neuronal cell surfaces (138,
151). Recently, additional molecules similar to
VEGF and capable of increasing capillary
permeability were found in snake venom,
suggesting that the family may be even larger
(67, 105). The receptors have partly
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overlapping but independent roles in the
vascular development and maintenance. The
expression levels of these genes modulate the
abundance of different types of vessels in
tissues. Other factors that are involved in the
regulation of blood and lymphatic vessels, are
the angiopoietins (Ang), ephrins and platelet-
derived growth factors (PDGFs), which all act
together in a co-ordinated manner during
vessel formation (18, 30, 64). Interestingly,
certain highly differentiated endothelia may
have additional structurally unrelated
regulators, such as EG-VEGF (112).
                       
Figure 3. Receptor binding specificity of VEGFs.  Growth factors activating
VEGFR-1 and VEGFR-2 mediate the angiogenic signals, whereas lymphangiogenesis
is mainly obtained via VEGFR-3.
VEGF
VEGF, discovered in 1989, is a major mediator
of both vasculogenesis and angiogenesis
(reviewed in (53)). In endothelial cells VEGF
binds to VEGFR-1 and VEGFR-2 (52). VEGF is
expressed as several isoforms consisting of
polypeptides of different sizes (121, 145, 165,
183, 189 and 206 amino acid residues), which
are all formed from the same gene by
alternative splicing. They differ in their ability
to interact with extracellular matrix
components and with NRP-1 (41, 83, 145, 178,
186). These isoforms are thought to have
distinct, but overlapping functions in
angiogenesis. VEGF is also known as vascular
permeability factor, as it promotes the
extravasation of fluid and plasma proteins,
including fibrin, from the blood vessels (45,
172). The increase in microvascular
permeability and tissue deposition of fibrin is
considered to enhance the migration of
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endothelial cells in the extracellular matrix
(46).
VEGF is essential for embryonic vasculogenesis
and angiogenesis. Inactivation of only a single
VEGF allele in mice resulted in embryonic
lethality due to defective angiogenesis (31,
54). Also a reduced number of hematopoietic
cells was observed. In mutant mice lacking the
164 and 188 amino acid isoforms of VEGF, half
of the mice did not survive due to defects in
for example postnatal angiogenesis in the
myocardium, suggesting that the other forms
of VEGF cannot completely replace the action
of the others (34).  Partial inhibition of VEGF
by a soluble extracellular form of VEGFR-1
resulted in increased mortality and impaired
organ development in the early postnatal
period (69). It was shown that in addition to
proliferation, VEGF is also required for the
survival of endothelial cells. Consistent with
this, other studies have also shown that VEGF
supports the survival of endothelial cells by
inducing the expression of anti-apoptotic
proteins in endothelial cells (6, 14, 70).
VEGF is important in the etiology of several
diseases characterized by pathological
angiogenesis such as psoriasis, rheumatoid
arthritis, and proliferative retinopathy
(reviewed in (53)). Consistent with this, the
expression of VEGF is potentiated in response
to hypoxia and by activated oncogenes as well
as by a variety of cytokines (74, 157, 174).
Upregulated VEGF expression contributes to
the development of solid tumors by promoting
tumor angiogenesis (59). Tumor inhibition
studies with neutralizing anti-VEGF antibodies
suggested that other angiogenic factors may
also be involved (102).  However, the VEGF
signalling pathway is currently considered as
one of the most promising targets for the
inhibition of tumor angiogenesis.
VEGF-B
VEGF-B is structurally closely related to VEGF
and binds one of its receptors, VEGFR-1 (136).
It has two splice variants, isoforms of 167 and
186 amino acids. They differ in binding to
heparan sulphates in extracellular matrix and
to NRP-1 (124). Both VEGF-B isoforms are able
to form heterodimers with VEGF, and perhaps
with other growth factors. This adds diversity
to their biological roles by allowing a variety
of combinations for cellular signal
transduction.
VEGF-B is produced in large quantities by the
developing myocardium and by muscle, bone,
pancreas, adrenal gland, and the smooth
muscle cell layer of several large vessels, but
not by endothelial cells (1). VEGF-B is likely to
act in a paracrine fashion as its receptor is
almost exclusively located on endothelial
cells. VEGF-B is a very weak endothelial cell
mitogen when produced in mammalian cells
(136), but otherwise its biological role is still
unclear. Mice lacking a functional VEGF-B
gene are healthy and fertile, but depending
on the genetic background may have a
conduction defect or reduced heart size (2,
13). The knockout mice display a striking
vascular dysfunction after coronary occlusion
and they show impaired recovery from
experimentally induced myocardial ischemia
(13). Considering such results, it is interesting
to note that while VEGFR-1 and VEGFR-2 were
expressed rather uniformly in the developing
vasculature, only VEGFR-1 was prominently
expressed in the human fetal coronary
endothelium (148). These results suggest a
role for VEGF-B in the coronary vasculature
and potential clinical use in therapeutic
angiogenesis.
PlGF
PlGF was discovered in the human placenta
and it is about 50% homologous to VEGF (121).
PlGF binds to VEGFR-1 and its heparin binding
isoform, PlGF-2, also binds to NRP-1 (28, 129,
144).  Binding of PlGF to VEGFR-1 is
considered to increase the proportion of VEGF
available to activate VEGFR-2 thereby
potentiating the angiogenic properties of
VEGF (144). A lack of PlGF has no major effect
on embryonic development, even in
combination with a loss of VEGF-B (33).
However, loss of PlGF impairs angiogenesis
associated with tumors, ischemia, myocardial
infarcts and experimental retinopathy, and
leads to prolonged healing of incisional skin
wounds (33). During collateral growth after
ligation of the femoral artery, PlGF was found
to be essential for plasma extravasation,
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monocyte recruitment and for the growth of
endothelial and smooth muscle cells. These
results indicate that PlGF activates membrane
bound VEGFR-1 and specifically potentiates
the angiogenic response to VEGF. In contrast
to the essential role of VEGF in physiological
and pathological angiogenesis, the role of
PlGF is restricted to pathological vessel
formation.
VEGF-C and VEGF-D
VEGF-C was cloned from human prostate
carcinoma cells and its mature form consisting
of the VEGF homology domain is 30% identical
to VEGF165 (90). VEGF-C is synthesized as a
preproprotein from which a stepwise
proteolytic processing generates several
forms, with sequentially increasing binding
and activity for its receptors, VEGFR-2 and
VEGFR-3 (Fig. 4) (91). Like VEGF, VEGF-C
stimulates the migration of endothelial cells,
and increases vascular permeability and
endothelial cell proliferation but at higher
concentrations than VEGF. These signals for
endothelial cells are probably mediated
through VEGFR-2 in blood vascular endothelial
cells and generally via VEGFR-3 in the
lymphatic endothelial cells (91, 93). Unlike
VEGF, the expression of VEGF-C does not
appear to be regulated by hypoxia (49), but is
increased in response to proinflammatory
cytokines suggesting a role in inflammatory
responses (160). The pattern of VEGF-C
expression in embryos suggests that it plays a
role in the development of the lymphatic
vessels, since a paracrine expression pattern is
seen between VEGF-C and VEGFR-3 at sites
where the first lymphatic sprouts occur (108).
Conversely, VEGF-C is already expressed
before the emergence of the lymphatics,
which also suggests the involvement in
vasculogenesis/angiogenesis during early
development.
VEGF-C regulates physiological and
pathological blood vessel growth in vivo. It is
able to stimulate angiogenesis in the mouse
cornea and in limb ischemia (29, 204). On the
other hand, VEGF-C has been shown to
regulate the growth of lymphatic vessels in
various experimental models. Overexpression
of VEGF-C in skin keratinocytes leads to
dermal lymphatic vessel hyperplasia (88).
Signalling via VEGFR-3 alone was shown to be
sufficient for the lymphangiogenesis, since
transgenic mice overexpressing a mutant form
of VEGF-C, which has lost its capacity to bind
VEGFR-2 and only binds and activates VEGFR-3
(VEGF-C156S (89)), was able to induce a
similar phenotype (194). VEGF-C was also
studied in the mature, differentiated
chorioallantoic membrane (CAM), that
contains lymphatic vessels mainly around
arterioles and veins (134). In this assay, VEGF-
C acts as a highly specific lymphangiogenic
factor. However, when VEGF-C was applied to
the early CAM, where the lymphatics have not
yet developed, it promoted angiogenesis. The
angiogenic vs. lymphangiogenic responses to
VEGF-C may depend on the degree of
proteolytic processing of its precursor, and on
the expression of it receptors in the blood vs.
lymphatic endothelial cells of the target
tissue. VEGF-C also has synergistic effects
with VEGF, during the induction of
angiogenesis, and this effect is more
prominent in cells expressing both of its
receptors (150). In addition, VEGF-C can
compete with VEGF in binding to VEGFR-2.
VEGF-D (also known as c-fos-induced growth
factor or FIGF) is the most recently discovered
member of the mammalian VEGF family (3).
It shares 61% sequence identity with VEGF-C
and these two growth factors bind to the same
receptors on human endothelial cells. VEGF-D
is proteolytically processed similarly to VEGF-
C and the proteolytic processing also appears
to regulate VEGF-D biological activity and
receptor specificity (181). Interestingly, in
mice VEGF-D binds only to VEGFR-3,
suggesting that VEGF-D may have a somewhat
different function in mouse and man (9). This
is uncommon within the VEGF family as these
homologous and evolutionary conserved
growth factors are assumed to exhibit similar
receptor binding characteristics in different
species. VEGF-D has been shown to be able to
stimulate the proliferation of endothelial
cells, and shows angiogenic properties in vitro
and in vivo (127). Like VEGF-C, it was also
shown to be lymphangiogenic when
overexpressed in skin keratinocytes (194).
Little is known about the expression of VEGF-D
in physiological conditions, but its mRNA has
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been observed in the developing melanocytes
and fibroblasts, lung mesenchyme and in the
adult vascular wall (4).
                      
Figure 4. Proteolytic processing of the VEGF-C and VEGF-D protein. The growth
factors are synthesized as prepropeptides containing N- and C- terminal propeptides
(N and C) and a VEGF-homology domain (VHD). Proteolytic processing generates
several forms with increased binding towards VEGFR-2 and VEGFR-3. This may
regulate the angiogenic and lymphangiogenic properties of the VEGF-C and VEGF-D.
VEGF-E
A VEGF homologue, VEGF-E, was recently
discovered in the genome of the parapoxvirus,
Orf virus, that infects sheep, goats, and
occasionally humans (120). Infection by this
virus causes proliferative skin lesions in which
extensive capillary proliferation and dilation
are prominent histological features. Several
strains of the virus encode different VEGF-E
variants, which bind specifically to VEGFR-2
and NRP-1 and are able to stimulate
endothelial cell mitogenesis and vascular
permeability (133, 201). VEGF-E is not
essential for viral replication but rather plays
an important role in modulating the host
environment during infection.
                                                                    VEGFR-3 in Angiogenesis and Lymphangiogenesis    13
VEGFR-1 & VEGFR-2
VEGFR-1 and VEGFR-2 are important in blood
vascular endothelial cell proliferation,
migration and survival. Mice carrying a
homozygous disruption in either of the two
VEGF receptors die during early development
due to defects in both vasculogenesis and
angiogenesis. Embryos lacking functional
VEGFR-2 are lacking mature endothelial and
hematopoietic cells (173). In contrast, VEGFR-
1 deficient mice have normal hematopoietic
progenitor cells and endothelial cells that
migrate and proliferate but do not assemble
into tubes and functional vessels (61). More
recent studies have shown that an excessive
proliferation of endothelial progenitors is the
main factor leading to this disorganization
(62). This supports the view that VEGFR-1 is a
negative regulator of VEGF-induced
vasculogenesis in embryos.
VEGFR-1 alone has been shown to induce weak
mitogenic signals in vitro (110), but it is
thought that VEGFR-2 is the major receptor
transducing the effects of VEGF in endothelial
cells. For example, VEGF-E and site-directed
mutants of VEGF, which bind only to VEGFR-2,
stimulate endothelial cells similarly to VEGF
(70, 101, 128, 201). VEGF also provides
survival signals for endothelial cells via
VEGFR-2 (70). Outside of the vascular system,
VEGFR-1 is expressed in monocytes and
macrophages, placental throphoblasts and
renal mesangial cells, and VEGFR-2 in
hematopoietic stem cells, megakaryocytes,
platelets, retinal progenitor cells and in
circulating endothelial precursor cells (11, 36,
38, 98, 207, 208). Despite the importance of
these receptors during embryonic blood vessel
development, VEGFR-1 and VEGFR-2 appear to
be downregulated in the quiescent adult
endothelium.
VEGFR-3
VEGFR-3 was cloned from a human leukemia
cell line and from human placenta (65, 142).
Two isoforms of VEGFR-3 have been
described, designated VEGFR-3s (short) and
VEGFR-3l (long), which differ as a result of
alternative splicing. The long form is the
predominant    form   in  most   tissues.      An
endogenous retroviral genome appears
responsible for the short isoform in humans,
but this form is missing from mice (84).
VEGFR-3 is initially expressed in all embryonic
vasculature, but during development its
expression in blood vessels decreases and
becomes restricted to the developing
lymphatic vessels (93). VEGFR-3 deficient
embryos die as a result of a defect in the
remodelling of the primary vascular network
and cardiovascular failure at midgestation,
before the lymphatic vessels start to develop
(44). In adults the expression of VEGFR-3 is
mainly restricted to lymphatic endothelial
cells, where it serves as a molecular marker
for these vessels (92, 93).  These results
suggest that VEGFR-3 plays a dual role, in
embryos in cardiovascular development and in
adults in the regulation of the lymphatic
vessels.
In adults, VEGFR-3 is expressed in a subset of
capillary and venous endothelium, although it
is absent in endothelia of all large blood
vessels (147). VEGFR-3 is re-activated in the
blood vessel endothelium in certain
pathological conditions and upregulation of
VEGF-C/VEGF-D ligands may accompany this
(4, 168, 193). Similarly, VEGFR-2 can be
expressed by both blood vascular and
lymphatic endothelia (148). During wound
healing, acute inflammation is followed by the
deposition of fibrin and connective tissue and
the growth of blood vessels into the
granulation tissue. Most blood vessels then
regress as the wound is remodelled into scar
tissue. VEGFR-3 positive lymphatic vessels
have been observed to sprout from pre-
existing lymphatics and grow into the
granulation tissue in healing skin wounds
(141). These lymphatic vessels persisted in the
wound for some time but regressed as the
healing proceeded. This suggests that
transient lymphangiogenesis is needed during
wound healing, in parallel with angiogenesis.
On the other hand, no lymphatic vessels were
seen in chronic human wounds (141). The
absence of lymphatic vessels may contribute
to the impaired healing in these conditions.
The angiogenic vessels in wound healing
remained negative for VEGFR-3, suggesting
that there are differences in the regulation of
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angiogenesis in various pathological
conditions.
Little is known about the characteristic
features of lymphatic endothelial cells, mainly
because isolated lymphatic endothelial cells
have not been available for molecular studies.
Recently, primary cultures of human dermal
endothelial cells were shown to consist of
distinct lines of blood vascular and lymphatic
endothelial cells (106, 125). Cells of the
lymphatic lineage could be isolated by
antibodies against VEGFR-3 or podoplanin.
Signalling via VEGFR-3 was shown to be
critical for growth, migration, and survival of
the isolated lymphatic endothelial cells (125).
Also VEGFR-2 was detected in the lymphatic
endothelial cells, suggesting that activation of
both VEGF-C receptors may be required for
their maximal survival (125, 148).
Neuropilins
NRP-1 and NRP-2 are transmembrane receptor
proteins that are required for axon guidance
and, according to recent discoveries, also for
the regulation of angiogenesis (72, 177, 178).
Both neuropilins bind certain isoforms of
VEGF, VEGF-B, VEGF-E and PlGF-2 (124, 129,
178, 201). NRP-1 is expressed in the tips of
actively growing axons of particular classes of
neurons (63), but also in the blood vascular
endothelial cells and in certain tumor cells
(177, 178). NRP-1 enhances VEGF165 binding to
VEGFR-2 and VEGF-mediated chemotaxis.
Embryos lacking functional NRP-1 die due to
defects in VEGF mediated angiogenesis and
subsequent cardiovascular failure (99) and
ectopic overexpression of NRP-1 leads to an
excess of dilated blood vessels and
hemorrhage, apparently due to inappropriate
VEGF activity (104). Mice having targeted
deletion of NRP-2 are viable, but have defects
in the development of central and peripheral
nervous systems (37, 71). Recently, NRP-2 has
been shown to bind VEGF-C and to be
expressed together with VEGFR-3 in the
endothelial cells of a sub-population of the
lymphatic vessels (94).
Angiopoietins and Tie-Receptors
Tie-1 and Tie-2 (Tek) are expressed in
endothelial cells throughout embryonic
development as well as in hematopoietic
progenitor cells (42). Gene targeting
experiments indicate that Tie-1 and Tie-2 are
essential to the angiogenic expansion of the
vasculature during development. In mouse
embryos lacking the Tie-2 receptor
endothelial cells are present in slightly
reduced numbers and are assembled into
tubes, but the vessels remain immature,
lacking branching networks and proper
organization into a hierarchy of large and
small vessels (43, 169). The vessels lack
intimate encapsulation by periendothelial
support cells, and the endocardium is only
loosely attached to the myocardium. Thus Tie-
2 appears to control the capability of
endothelial cells to recruit stromal cells,
which stabilize the vessel structure and
modulate the function of blood vessels (76).
Tie-1 is required cell autonomously for
endothelial cell survival and extension of the
vascular network during the later part of
embryogenesis (155, 169). Vasculogenesis
proceeds normally in embryos lacking both
Tie-1 and Tie-2, since the angioblasts
differentiate normally (154). It appears that
one of the earliest critical functions of these
receptors concerns endocardial development,
but that rescue of the embryos is possible if
one bypasses the critical period using
transgenic expression of Tie-2 (Dr. D. Dumont,
personal communication).
Ang-1 and Ang-2 bind to Tie-2 with similar
affinities, but only Ang-1 can activate the
receptor directly. Ang-2 is capable of
inhibiting the effects of Ang-1 in endothelial
cells in short-term experiments. However, if
endothelial cells of human umbilical vein are
stimulated with Ang-2 for longer periods,
activation of the Tie-2 receptor is obtained
(185). Ang-2 is also capable of stimulating Tie-
2 in transfected nonendothelial cells. Thus,
Ang-2 has both agonistic and antagonistic
properties, which may relate to its ability to
dimerize or oligomerize less efficiantly than
Ang-1, or to binding to an inhibitor that needs
to be downregulated.
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Ang-1 is widely expressed in both embryonic
and adult tissues (184). Ang-2 is also
expressed in embryos around large vessels,
but in adults the expression pattern is
restricted to sites of physiological
angiogenesis, where vascular remodelling
occurs (122). Transgenic overexpression of
Ang-2 under the Tie-2 promoter in the
embryonic endothelium indicates that Ang-2
inhibits the recruitment of supporting
perivascular cells, resulting in a phenotype
similar to that of the Ang-1 knockout embryos
(184). In adults, Ang-2 allows vascular
remodelling, which otherwise is restricted by
encapsulation by the basement membrane and
periendothelial support cells. When the
expression of Ang-1 overcomes that of Ang-2,
such remodelling ceases and vessels stabilize
(reviewed in (64)).
Several lines of evidence indicate that there is
significant collaboration between VEGF, Ang-2
and Ang-1 in angiogenic processes. Vascular
regression is associated with very high levels
of Ang-2 in the absence of activating survival
signals from VEGF. In the skin of transgenic
mice VEGF increases the number of
capillaries, whereas Ang-1 causes a massive
enlargement of postcapillary venules (188).
Interestingly, Ang-1 was able to rescue the
permeability effects of VEGF (187).  Co-
expression of both factors was required to
obtain an increased number of large vessels in
transgenic mice.  Identification of the
ligand(s) for the Tie-1 receptor should provide
further insights into the mechanistic basis for
this asymmetric regulation of vascular
development. Ang-2 may also be involved in
the regulation of lymphatic vessels, since
knock out mice lacking functional Ang-2 have
chylous ascites with a disorganized and leaky
l ympha t i c  va s cu l a tu re  ( pe r sona l
communication with Dr. G. Thurston and Dr.
G. Yancopoulos).
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Table 1.
Summary of the biological roles of VEGFs, VEGFRs, TIEs and  Angiopoietins
Gene Phenotype in gene
deficient mice
Lethal Biological role
VEGF defective blood vessel
development and blood islands
(31, 54)
-/-
E8-9
+/-
E11-12
vasculogenesis,
developmental and pathological
angiogenesis
VEGF-B 1) normal heart
development (2)
or
2) defective heart
development (13)
Viable modulates biological activity of
VEGF (?)
PlGF normal vascular development
(33)
Viable pathological angiogenesis,
amplifies responsiveness to VEGF
VEGFR-1 disorganization of vascular
system, increased number of
endothelial precursors (61, 62)
E 8.5 negative regulator of VEGF-
mediated angiogenesis ?
monocyte recruitment
VEGFR-2 no mature endothelial or
hematopoietic cells (173)
E 8.5-
9.5
hemangioblast differentiation,
proliferation and migration, vascular
permeability
VEGFR-3 pericardial effusion, defective
large blood vessels (44)
E 9.5-
10.5
vascular remodelling, migration and
survival of lymphatic ECs
NRP-1 anomalies in cardiovascular
system and efferent nerve
fibers (99, 104)
E12.5 axon quidance in PNS,
cardiovascular development,
enhances effect of VEGF165
NRP-2 defects in the development of
central and peripheral nerves
(37, 71)
Viable axon quidance
Ang-1 fewer branches,
homogeneously sized vessels,
defects in endocardium and
myocardium (184)
E12.5 recruitment of perivascular cells,
vessel stabilization
Tie-1 defective angiogenic expansion
and integrity of vessels (155,
169)
E10.5 vascular network formation, survival
of EC
Tie-2 defects in maturation and
organization of blood vessels
(169)
E10.5 recruitment of perivascular cells,
vessel stabilization
EC; endothelial cell, PNS; periferal nervous system
PDGFs
The platelet-derived growth factor (PDGF)
family consist of homodimers or heterodimers
made from the pairwise assembly of the
related PDGF polypeptide chains (reviewed in
(79)). These effects of the PDGFs depend on
the target cell type, in particular on the cell’s
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repertoire of PDGF receptors, α and β. The α
receptor can bind PDGF-A, PDGF-B and PDGF-
C chains, whereas the β-receptor is selective
for the PDGF-B and PDGF-D chains (16, 18,
115). Based on the gene deficient studies,
both receptors are essential for embryonic
development. PDGF-A and PDGFR-α are
prominently expressed at sites of epithelium-
mesenchyme interaction, whereas PDGF-B
takes part in blood vessel development (81,
116, 140). PDGF-D is the first known PDGFR-β-
specific ligand, and its unique receptor
specificity indicates that it may be important
in the development and pathophysiology of
several organs. The expression of PDGF-C and
PDGF-D in the arterial wall and cultured
vascular cells suggests that they can transduce
proliferation/migration signals to pericytes
and smooth muscle cells (192).
During blood vessel development, PDGF-B is
expressed in endothelial cells, while pericytes
and smooth muscle cells covering the blood
vessels express PDGFR-β, indicating paracrine
signalling between these two cell types (81,
116). Targeted gene disruption studies of
PDGF-B or PDGFR-β gave similar phenotypes.
In both mouse strains, blood vessel
development was deficient because of the
inability of blood vessels to attract pericytes
(80, 81, 116). Also the development of the
renal and hematopoietic systems were
affected (114, 179). Lack of pericytes in
embryonic angiogenesis leads to hyperplasia
of endothelial cells, supporting the notion
that pericytes inhibit endothelial cell
proliferation (80). Smooth muscle cell
proliferation in response to the release of
growth factors from neighboring cells is one
mechanism postulated to account for the
development of atherosclerotic lesions. PDGFs
may be involved in initiation and progression
of atherosclerotic changes in arterial intima
by promoting proliferation of smooth muscle
cells of the vascular wall (17, 130). These
molecules may also have an important role in
tumor biology, since expression of the mRNA
of the receptors and ligands has been
observed in wide variety of human tumors
(79).
Ephrins
Before the heart starts to beat and circulate
blood, the vascular hierarchy must be
organized and arteries and veins must be
ready to properly transport blood. In studies
of the ephrin family of molecules it has
become obvious that the fate of endothelial
cell is already marked in early embryonic
development when the whole endothelium is
still rather uniform in nature (reviewed in
(205)). Unlike ligands for other receptor
tyrosine kinases, the ephrins cannot act as
soluble mediators, but rather must be
membrane-bound in order to activate their
receptors. Interestingly, bidirectional
signalling was observed between the ligand
and receptor. Ephrin-B2 was shown to mark
future arteries while its receptor Eph-B4
reciprocally marks the venous endothelium
(195). Furthermore, embryos lacking Ephrin-
B2 displayed severe defects in vascular
remodelling in both arterial and venous
domains. These findings provide some of the
earliest known markers distinguishing the
arterial and venous endothelia. This data for
the first time shows the existence of
bidirectional signalling between these vessel
types. This suggests that the molecular
differences are at least partly programmed
genetically in arterial vs. venous endothelia
and that these differences may be critical to
normal development of the vasculature.
Markers for the lymphatic vessels
A major advance in the field of
lymphangiogenesis has come from the
discovery of lymphatic endothelium-specific
markers (Table 2). In addition to VEGFR-3,
other molecules have now been found to
express relatively specifically in lymphatic
endothelial cells. Podoplanin is a glomerular
podocyte membrane mucoprotein, which
occurs together with VEGFR-3 in the lymphatic
endothelium and in benign vascular tumors
and angiosarcomas, but is also expressed in
certain non-endothelial cells (22, 23). Prox-1,
a homeobox transcription factor, is involved in
the  sprouting   of  lymphatic   vessels      from
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embryonic veins during development (198).
Prox-1 is also expressed in nonendothelial
cells. The third marker, LYVE-1 (Lymphatic
vessel endothelial hyaluronan-receptor-1), is a
receptor for extracellular matrix/lymphatic
fluid glycosaminoglycan in lymphatic
endothelial cells (10). This molecule, which is
related to the CD44 receptor for hyaluronan,
is distributed equally among the luminal and
abluminal surfaces of lymphatic vessels and is
involved in the uptake of hyaluronan by
lymphatic endothelial cells and its transport
from the tissues to the lymph (153).
Recently, a β-chemokine receptor D6 was
shown to be present in a subset of lymphatic
vessels in the skin, intestine and lymphoid
tissues (131). Interestingly, lymphatic vessels
in most of the organs remained negative for
its expression. The existence of this receptor
on only a subset of lymphatics suggests a
functional heterogeneity within the lymphatic
vasculature. Consistent with this, recent
findings revealed the co-expression of NRP-2
and VEGFR-3 in lymphatic vessel endothelia of
the intestine, whereas dermal lymphatic
vessels did not show NRP-2 expression (94).
The mannose receptor of macrophages is also
expressed by lymphatic endothelia in addition
to macrophages and other non-endothelial
cells (117). The biological role of this receptor
in lymphatic vessels is not known, but it may
play a role in inflammation and immunity.
5’-nucleotidase and desmoplakin have also
been used to distinguish the lymphatic from
the blood vascular endothelium (170, 191) and
since lymphatic capillaries lack a continuous
basement membrane, immunohistochemistry
for extracellular matrix components type IV
collagen and laminin have also been used to
distinguish them from blood capillaries (12).
VEGFR-2 is occasionally expressed in
lymphatic endothelia (148) and Tie-1 and Tie-
2 may also have a role in lymphatic vessel
regulation, as they also appear in lymphatic
endothelia (92, 148) and mice deficient for
the Ang-2 have a lymphatic phenotype
(unpublished data of G. Thurston and G.
Yancopoulos).
Table 2. Markers for the lymphatic vessels
Molecule Protein class Biological effect
VEGFR-3 receptor tyrosine kinase on
endothelial cell  (92, 93)
lymphangiogenesis,
survival of LEC
LYVE-1 receptor for extracellular
matrix glycosaminoglycan (10)
transport of HA from tissues to
lymph nodes
PROX1 transcription factor (198) developmental lymphangiogenesis
Podoplanin integral membrane protein (23) unknown
β-chemokine
receptor D6
chemokine receptor in afferent
lymphatics (131)
leukocyte recirculation
Macrophage
mannose receptor
receptor in macrophages (117) phagocytosis of microbes,
viral endocytosis
Desmoplakin component of intercellular
adhering junction (170)
adhesion of LECs
LEC; lymphatic endothelial cell, HA; hyaluronan
Diseases of the lymphatic vessels
Pathological processes similar to those that
affect blood vessels, such as thrombosis,
inflammation, vessel wall hypertrophy, and
sclerosis may also occur to some extent in
lymphatic vessels. However, the slow flow of
the lymphatic fluid makes lymphatic disorders
more chronic in character (203). Lymphatic
vessel defects are associated with intense
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fibrosis and overgrowth rather than the
dramatic occlusive events such as occur in
blood vessels when the blood flow is
interrupted.
Lymphedema
An important function of the lymphatic vessels
is to regulate the pressure of interstitial fluid
in tissues by transporting excess fluid back
into the circulation. Clinical situations in
which the lymphatic system is involved
include lymphedema due to impaired
lymphatic drainage. This can be caused by
inflammatory or neoplastic obstruction of the
lymphatic vessels including accumulation of
ascites fluid due to lymphatic obstruction in
peritoneal carcinomatosis or edema of the
arm following surgery or radiotherapy for
breast cancer. Lymphatic filariasis is one of
the leading causes of permanent and long-
term disability globally. It is a parasitic
infection in the lymphatic vessels, which leads
to abnormal transport function, massive
edema and deformation of the limbs (203).
Primary lymphedema is a rare developmental
disorder, in which the transport failure of the
cutaneus lymphatic vessels results in
interstitial lymph fluid accumulation. Chronic
lymphatic dysfunction gradually results in
thickening of the skin, accumulation of
adipose tissue and dermal fibrosis of the
affected area (113). Recently, several groups
have reported linkage of congenital
lymphedema (Milroy’s disease) to the VEGFR-3
gene (50, 57, 202) with autosomal dominant
inheritance. This mutation was shown to lead
to reduced VEGFR-3 tyrosine kinase activity,
and subsequent failure in transducing
sufficient physiological VEGF-C/VEGF-D signals
to the lymphatic endothelial cells (95). In all
lymphedema families studied, the affected
individuals had only one mutant allele (86,
95), compatible with the results that
inactivation of both VEGFR-3 alleles in mice is
embryonic lethal (44). The mutation affecting
the biological activity of VEGFR-3 is probably
one cause of primary lymphedema, but some
other lymphedema genes also exist, for
example FOXC2 (51).
Kaposi’s sarcoma
Kaposi's sarcoma is a multicentric neoplasm
consisting of multiple vascular nodules
appearing in the skin, mucous membranes,
and viscera. Individuals with specific
conditions of immunodysregulation, especially
AIDS patients, develop these tumors.
Molecular and epidemiological studies indicate
that development of Kaposi’s sarcoma is
associated with infection by the human
herpesvirus-8 (HHV-8) (183). The nodules are
characterized by clusters of spindle-shaped
tumor cells and by prominent vasculature
consisting of small, irregular, endothelial-
lined spaces. It is thought not to be a
neoplastic transformation of cells in the
classic sense, but rather a manifestation of
excessive proliferation of the spindle cells. A
central question in the pathogenesis of
Kaposi’s sarcoma has long been, which cell
type in early lesions gives rise to the uniform
tumor cells of late nodules (66). The spindle
cells are most likely endothelial in origin, but
there has been controversy as to whether they
are of lymphatic or blood vascular derivation.
Vascular tumors
Vascular tumors can be divided into benign
tumors (hemangioma) and malignant vascular
tumors (angiosarcoma) and to the tumors of
lymphatic vessels (lymphangioma) and
perivascular cells (glomus tumors and
hemangiopericytoma). The molecular
characteristics of these tumors are so far
mostly unknown but VEGF and its receptors
have been shown to be expressed in the
endothelial cells of these tumors (162).
Although normal mesenchymal tissues show
VEGFR-3 in the lymphatic endothelial cells,
benign and malignant vascular tumors show
widespread VEGFR-3 expression, suggesting
that VEGFR-3 is upregulated in the
proliferating blood vascular endothelial cells.
This is consistent with the VEGFR-3 expression
in the embryonic developing vessels, as well
as reactivation in adult angiogenic blood
vessels (44, 193). Although strong expression
of VEGFR-3 would be consistent with
lymphatic differentiation, the extensive
erythrocyte content in the vascular lumina   of
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these lesions supports the idea that VEGFR-3
expression in these tumors reflects a
proliferative vascular phenotype rather than a
lymphatic phenotype. The expression of
VEGFR-3 among vascular proliferations
demonstrates that blood vessel endothelia can
acquire VEGFR-3 expression independently of
lymphatic vascular differentiation.
Classification of angiosarcomas is mostly
based on morphological criteria. It has been
suggested that some of the angiosarcomas
contain components of a lymphatic lineage,
but there was not proof of this (135). The
reactivity for VEGFR-3 was seen in poorly
differentiated angiosarcomas, indicating that
this receptor is conserved on malignant
transformation (146). Some cell populations in
angiosarcomas are positive for podoplanin,
which retains its lymphatic endothelial cell
specificity in vascular tumors, supporting the
idea of mixed expression of both blood and
lymphatic phenotypes in angiosarcomas (23).
Since expression of VEGFR-3 is seen in the
majority of benign and malignant vascular
tumors, but expression is less consistent in
malignant epithelioid vascular tumors and
absent in malignancies of nonendothelial
origin, VEGFR-3 could be used as a lineage
marker to identify endothelial cell
differentiation in the tumors. However,
further studies are needed to evaluate the
sensitivity and specificity of these markers.
Lymphangiomas result from abnormal
development of lymphatic vessels which
prevents lymph fluid draining from the
affected area. Lymphangiomas can originate
in most organs, although they are most often
found in the soft tissues of the head and neck
(cystic hygroma) and axilla. They consist of a
benign multicystic mass of dilated networks of
lymphatic channels.  Both VEGFR-3 and
podoplanin specifically stain the endothelia of
lymphangiomas and could be used for
diagnostic purposes (23, 92, 146).
Tumorigenesis and metastasis
Lots of evidence indicates that tumorigenesis
is a multistep process, and these steps reflect
the genetic alterations that drive the
progressive transformation (reviewed in (77)).
Whereas normal cells require mitogenic
signals before they can move from a quiescent
state into an active proliferative stage,
malignant cells are self-sufficient for the
growth signals, and insensitive to the growth-
inhibitory signals. Tumor cells generate many
of their own growth signals leading to
autocrine stimulation, thereby reducing their
dependence on stimulation from the normal
tissue micro-environment. It has long been
thought that tumors are independent from the
surrounding cells and their action, but now it
seems more likely that cancer development
depends upon interactions between tumor
cells and their benign neighbors. Tumors and
metastases tend to harbor complex mixtures
of several cell types that collaborate to create
a malignant growth, including fibroblasts,
immune cells and endothelial cells (58, 77).
The cells within aberrant proliferative lesions
initially lack angiogenic ability, preventing
their expansion. The ability to induce and
sustain angiogenesis seems to be acquired in
discrete steps during tumor development via
an angiogenic switch from vascular quiescence
to proliferation (77). In studies of transgenic
mouse tumorigenesis, angiogenesis was found
to be activated in midstage lesions prior to
the appearance of full-blown tumors (60).
These observat ions indicate that
neovascularization is necessary for the rapid
clonal expansion associated with the
formation of macroscopic tumors.  Tumors
appear to activate the angiogenic switch by
changing the balance of angiogenic inducers
and inhibitors (15, 58). Another regulatory
mechanism is the function of proteases, which
can control the availability of angiogenic
activators and inhibitors stored in the
extracellular matrix (40).
Tissue hypoxia is a fundamental angiogenic
stimulus characteristic also of malignant
tumors. The VEGF gene has been shown to
contain specific hypoxia-responsive elements
and to be upregulated in response to low
oxygen tension (55). Ang-2 levels are also
increased by hypoxia, suggesting a
collaboration of VEGF and Ang-2 in the
regulation of neovascularization of ischemic
tissue (reviewed in (111)). Tumor-derived
signals such as VEGF may specifically induce
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Ang-2 expression in tumor endothelia, and this
may be one important component in
angiogenic switch and in the formation of an
endogenous tumor microcirculation.
Vasculature and growth factors
in tumors
Microvascular density has been used as a
measure of tumor angiogenesis and its
correlations to tumor growth, metastasis and
prognosis has been studied (197). Levels of
VEGF are upregulated in a large number of
human tumors (reviewed in (55)) and
inhibition of VEGF activity results in the
suppression of growth of a wide variety of
tumor cell lines in murine models (56). It was
long thought that lymphatic vessels may be
lost, collapsed or could not penetrate in the
expanding primary tumors because they
cannot survive in the high interstitial pressure
inside the tumors (reviewed in (149)).
However, recently some intra-tumoral
lymphatic vessels have been observed (180).
Few data are available on the influence of
lymphatic microvessel density on survival in
cancer. In ovarian cancer, the lymphatic
vessel density had no influence on the
progression of the disease, and in cervical
cancer an increased amount of lymphatic
vessels may even be associated with a
favorable prognosis (19, 20). It is likely that
human tumors demonstrate heterogeneity
with regard to the presence or absence of
intra-tumoral lymphatics. The nature of the
marker may also influence the determination
of the lymphatic vessel density. VEGFR-3 has
been seen in the endothelial cells of the
proliferating vasculature in certain solid
tumors and vascular tumor cells of endothelial
origin (146, 193) and therefore cannot be used
alone to confirm the intratumoral lymphatic
vessel density. Other markers for the
lymphatic vessels, podoplanin and LYVE-1,
would better suit for this purpose and help in
elucidating any correlation between lymphatic
vessel density and tumor growth, metastases
and prognosis.
All VEGFRs are present in tumor
neovasculature and tumor cells have been
reported to be able to secrete VEGF, VEGF-B,
VEGF-C and VEGF-D (4, 55, 168). However, the
angiogenic switch is thought to be carefully
regulated and at least some specific genetic
events in tumor progression correlate with
lymphatic metastasis, suggesting that a
“lymphangiogenic switch” mechanism is also a
formal possibility.
Mechanisms of blood vascular
and lymphatic metastasis
The capacity to spread enables cancer cells to
escape the primary tumor mass and colonize
new areas in the body, where nutrients and
space are not growth limiting. Tumor cell
dissemination is mediated by mechanisms
including invasion, spread via blood or
lymphatic vessels or direct seeding of body
cavities or surfaces (39).  Although the
biochemical mechanisms are not completely
understood it is thought that the metastatic
spread of a tumor is not a random process.
Distinct patterns of metastasis can be
discerned which vary from tumor type to
tumor type. A common metastatic pattern for
carcinomas is that regional lymph nodes are
often the first organs to develop metastases
either draining via pre-existing afferent
lymphatic vessels and/or via newly formed
lymphatic capillaries. This pattern of
metastasis is central to the utility of the
sentinel lymphnodectomy as a surgical
technique. However, not all tumors and tumor
types metastasize to the regional lymph nodes
first (161). The mechanisms determining
whether regional lymph nodes or other sites
first develop metastases remain poorly
understood. In fact, most disseminated tumor
cells have a limited life span and only a few
develop into cl inically detectable
micrometastases, but identification of those
occult tumors cells, and prevention of their
growth and spread would be of great clinical
significance.
VEGF-C, VEGF-D and tumor
metastases
VEGFR-3 may play an important role in the
formation of  tumor- induced neo-
vascularization, since it is expressed in
capillary vessels during tumor angiogenesis
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(146, 193). Inactivation of VEGFR-3 by
neutralizing antibodies suppressed tumor
growth by destabilizing large vessels in tumor
xenografts in mice. Micro-haemorrhages were
seen in these vessels, suggesting that VEGFR-3
could be involved in maintaining the integrity
of the endothelial cell lining in the
neovasculature (107). Frequent administration
of VEGFR-3 antibody was required for the
suppression of tumor growth but the
architecture of the non-angiogenic blood and
lymphatic vessels remained unaffected. It has
also been shown that even a prolonged
suppression of VEGF activity in adult mice has
no effect on the maintenance of the vascular
system, though it suppressed angiogenesis
severely in embryos (69). The fully established
blood and lymphatic vessels seem to be
resistant to treatment with these kinds of
anti-angiogenic agents.
Recent work using experimental models has
highlighted the role of VEGF-C and VEGF-D in
tumor biology. Transgenic mice overexpressing
VEGF-C in ß-cells of the endocrine pancreas
developed extensive lymphangiogenesis
around the endocrine islets of Langerhans
(126).  Furthermore, when tumors were
induced in these VEGF-C overexpressing islets,
metastatic tumor cell aggregates of ß-cell
origin were observed in the surrounding
lymphatic vessels. These mice also frequently
developed metastases in the lymph nodes,
which drain the pancreas, whereas tumors in
mice lacking the VEGF-C transgene never
metastasized nor were tumor cells observed
inside the lymphatic vessels (126). Similarly,
human breast cancer cells expressing ectopic
VEGF-C were  shown to  induce
lymphangiogenesis in and around the
orthotopically implanted tumors (97, 176).
However, VEGF-C did not have a significant
effect on angiogenesis although it increased
tumor growth. Increased spreading of the cells
to the regional lymph nodes was observed and
the degree of tumor lymphangiogenesis
correlated with lymph node metastases
(Mattila et al., submitted for publication and
(176)). VEGF-C induced tumor growth,
lymphangiogenesis and intra-lymphatic tumor
growth was inhibited by adenoviral expression
of the soluble VEGFR-3 receptor (97).
VEGF-D was also shown to promote the
metastatic spread of tumor cells via the
lymphatics (180).  In  addi t ion  to
lymphangiogenesis and increased metastases,
the tumors secreting VEGF-D also had an
increased growth rate and tumor angiogenesis.
The growth of the tumor, angiogenesis and
formation of metastases were inhibited by
neutralizing antibodies against VEGF-D. The
differences between the tumor angiogenic
properties of VEGF-C and VEGF-D may be due
to differences in their proteolytic processing
in different tumors. Some of the
heterogeneity in the effects of these growth
factors may also result from variable
expression of their receptors, VEGFR-2 and
VEGFR-3, on the blood vascular and lymphatic
endothelia. In particular, in the above case,
enhanced tumor angiogenesis was probably
obtained for VEGF-D because of its increased
proteolytic processing, which resulted in an
increased affinity to VEGFR-2 (180), when
compared to the VEGF-C models. Also, intra-
tumoral lymphatic vessels were observed in
tumor xenografts (97, 176, 180), but not in
the transgenic tumors (126), which may be at
least partially explained by the trapping of
vessels in between the rapidly growing tumor
foci in the xenografts. On the basis of these
observations, tumor vessel formation can be
dissected into pathways that preferentially
activate angiogenesis via VEGFR-2 and
pathways that activate lymphangiogenesis
driven by VEGFR-3, although there is evidence
that the receptors occasionally share
overlapping expression patterns (148).
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Figure 5. Angiogenesis and lymphangiogenesis in tumors. At certain stage tumor
starts to secrete growth factors that induce the angiogenic and/or lymphangiogenic
responses. This allows the spread of metastatic tumor cells via blood or lymphatic
vessels.
It is still unknown whether VEGF-C or VEGF-D
expression also promotes lymphangiogenesis in
human tumors, and if so, does this increase
the rate of metastasis to the lymph nodes.
VEGF-C expression has been detected in about
half of human cancers analyzed (168). In
breast cancer VEGF-C expression seems to
correlate with lymph node positive tumors,
whereas VEGF-D may be expressed
predominantly in inflammatory breast
carcinomas, suggesting that these growth
factors have distinct roles in various tumors
despite their biochemical similarities (109). A
number of reports have described a
correlation between VEGF-C expression in
human tumors and the formation of
metastases in regional lymph nodes. So far,
VEGF-C levels in primary tumors have been
shown to correlate significantly with lymph
node metastases in thyroid, prostate, gastric,
colorectal, lung and eosophageal carcinomas
(5, 25, 103, 132, 190, 206). Less is known
about the presence of VEGF-D in human
tumors, but VEGF-D was shown to be
upregulated in human melanomas when
compared to melanocytes (4). In melanomas
VEGF-D was detected in the tumor cells and in
vessels adjacent to immunopositive tumor
cells, but not in vessels distant from the
tumors. This suggests that VEGF-D binds to the
endothelial cells of nearby vessels and
contributes in a paracrine manner to the
regulation of tumor angiogenesis.
It is not known to what extent tumor cell
secreted factors are directly responsible for
the large lymphatic vessels occasionally
detected around human tumors. Inflammatory
cells for example could contribute to the
lymphangiogenesis, as VEGF-C is chemotactic
for macrophages and induced by
proinflammatory cytokines (49, 160). It is not
clear whether the newly formed lymphatic
vessels mature in a way similar to the blood
vessels, or whether they are more prone to
tumor cell invasion for example because of
differences in the expression of adhesion
receptors. VEGF is known to be able to
upregulate the expression of adhesion
molecules in the vasculature, but such a role
for VEGF-C and VEGF-D is not known.
Therapeutic approaches
Anti-angiogenic and anti-
metastatic therapy
Despite advances in surgery, radiotherapy and
chemotherapy, the prognosis of many cancers
remains poor. One of the goals of gene
therapy in cancer treatment is to target the
therapeutic gene to all tumor cells, as each
untreated tumor cell has the potential to
progress and to metastasize. The purpose of
combining conventional cancer therapy with
anti-angiogenic agents is that the anti-
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vascular effects of the chemotherapy and
radiotherapy are selectively enhanced in the
cells of newly formed vessels, for example
when survival signals mediated by VEGF are
blocked (reviewed in (53, 100)). However, one
needs also to consider the unwanted toxic
effects of the cancer therapy on the
vasculature, some of which could be
alleviated by provision of vascular survival
factors (143). Therapy resistance in tumor
cells depends on tumor cell heterogeneity,
genetic instability and a high mutation rate.
Compared to conventional cytostatics, there
may well be less of a risk of resistance to anti-
angiogenic agents, since the endothelial cells
are assumed to be genetically more stable and
have a lower mutation rate than the tumor
cells (21, 53). However, the immature nature
of tumor blood vessels should provide a
therapeutic window where the tumor vascular
endothelium can be targeted leaving the rest
of the vasculature intact.
Several anti-angiogenic agents, alone or in
combination with conventional therapies,
have advanced to clinical trials. Many of them
target angiogenic growth factors, their
receptors or downstream signalling. For
example, neutralizing antibodies against VEGF
or VEGFR-2 have been used in the treatment
of various solid tumors with and without
combination with traditional cancer therapy
(32). Although pre-clinical results are
promising it is not yet clear how anti-
angiogenic therapies will perform clinically.
Mechanisms of angiogenesis differ in various
tissues. Therefore therapeutic inhibition of
angiogenesis needs to be modified for each
target tissue (56). There is evidence indicating
that different types of tumor have distinct
molecular mechanisms to activate the
angiogenic switch. Whether a single anti-
angiogenic molecule will suffice to treat all
tumor types, or whether an ensemble of such
molecules needs to be developed, remains to
be seen. The differences between the surface
molecules of blood vascular and lymphatic
endothelia can be taken into account when
targeting therapeutic agents selectively to
tumor lymphatic vessels. This would increase
the potency of the drug in the target tissue
and limit the possibility of side effects (8,
163). Methods such as cDNA microarray
analysis and phage display screening have
been used to identify such markers. Toxic or
vaso-occlusive therapy has already been used
to target directly tumor vasculature (7, 47,
73). The targeting of lymphatic vessels in
human tumors would help in imaging these
vessels and facilitate studies into the role of
lymphatic vessels in the metastatic processes.
Anti-cancer drugs specifically targeted to
peritumoral lymphatic vessels could be used
to inhibit lymphatic metastasis. However, the
destruction of these vessels would further
elevate the high interstitial pressure inside
the tumors impairing the delivery of other
drugs. As VEGF-D expression has been shown
to become upregulated by direct cell-cell
contacts, the increased intratumoral pressure
could increase close contacts between the
tumor cells and lead to a compensatory
increase of the lymphangiogenic growth factor
levels (139). Increased intratumoral pressure
could also enhance the likelihood of
hematogenous metastasis (32, 182).
Gene and recombinant protein
therapy of myocardial and
peripheral ischemia
Ischemic heart disease stems from poor
oxygenation of the heart muscle as a
consequence of coronary vessel obstruction
(39). Promoting angiogenesis in this situation,
or in ischemia of the lower limb, may have a
positive impact by increasing collateral vessel
formation. Various angiogenic approaches to
treating ischemic diseases are already in
clinical trials (56, 87). Many of them involve
the delivery of VEGF to ischemic tissue in
order to stimulate the growth of new vessels.
One outstanding question is whether a single
angiogenic factor can promote functional and
sustainable angiogenesis, or if a combination
of angiogenic molecules is required. For
example, vessels induced by VEGF are leaky
and tortuous, so it may be possible to control
leakiness by combining VEGF with Ang-1, as
was done in a mouse model (187).
Recombinant VEGF-C may also be used as a
therapeutic angiogenic growth factor in the
treatment of tissue ischemia, possibly even in
combination with VEGF (82). The angiogenic
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activity of VEGF-C in ischemic conditions may
relate to the increased expression of VEGFR-2
and the presence of relatively high
endogenous VEGF levels in such conditions. On
the other hand, lymphangiogenesis has never
been studied in ischemia, but no evidence
exists at present concerning the possible role
of hypoxia in the regulation of the lymphatic
vessels. The findings that VEGF has an
important role in bone angiogenesis and
endochondral bone formation suggest that
these factors could also be used to enhance
revascularization in orthopedic conditions
such as nonhealing fractures (68).
An important question concerning the pro-
angiogenic therapies is how the therapeutic
molecules should be administered. Is it
possible to deliver systemically a potent
molecule like VEGF in therapeutic quantities
without causing toxic side effects, like
hypotension or edema and could these be
prevented by local therapy? Suitable methods
and routes of therapy would also avoid the
infiltration of inflammatory cells, such as
macrophages, which express VEGFR-1. It is not
clear for how long these factors should be
administered, whether the therapy leads to a
functional vasculature and whether the
vessels will regress upon the completion of
therapy. At least some of the vessels
generated in response to VEGF gene therapy
eventual ly  stabi l ize  and acquire
periendothelial structures (152). Such
stabilization of vessels may depend on the
level of intraluminal blood flow. However,
concern about potential side effects, such as
inappropriate blood vessel growth in patients
with diabetic retinopathy or solid tumors, has
decreased the enthusiasm for the use of these
powerful agents (196).
Therapeutic lymphangiogenesis
The discovery of specific genes involved in the
regulation of lymphatic vessels, and in the
pathology of lymphedema should make the
design of more targeted treatments for this
disease possible. As transgenic VEGF-C/D
overexpression is able to induce the
postnatatal growth of new lymphatic vessels
in the skin (88, 194), treatment using these
molecules may also be useful in lymphedema
patients. Subcutaneous viral gene transfer of
VEGF-C in mice has already been shown to
induce lymphangiogenesis within two weeks of
treatment (48, 94). The effect of VEGF-C was
explored by both gene therapy and transgene
approaches in the Chy lymphedema mouse
model (94). These mice, like human patients,
have a heterozygous mutation in the VEGFR-3
gene, resulting in partial loss of VEGFR-3
activity, and features typical for lymphedema
(94, 119, 118). This impairs the development
of the cutaneous lymphatic vasculature and
leads to hypoplastic, non-functional vessels.
When VEGF-C was overexpressed in the skin of
Chy mice, growth of functional cutaneus
lymphatic vessels was induced, suggesting that
VEGF-C/D gene therapy may be applicable to
human lymphedema. Such therapy could also
be used in non-hereditary, regional forms of
lymphedema resulting from trauma, surgery or
lymphatic vessel destruction after filariasis. As
VEGFR-3 signalling plays a role in lymphatic
endothelial cell survival (123, 125), long term
growth factor expression may be needed to
obtain lymphangiogenesis, and maintain these
vessels in chronic lymphedema. The functional
characteristics of the newly formed lymphatic
vessels, for example their connections to
draining lymphatic vessels, still require
additional studies.
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Aims of the study
Previous studies showed that VEGFR-3 is
expressed in lymphatic endothelial cells and
that the growth factors VEGF-C and VEGF-D
bind and activate it. This study was done to
obtain more information about the biological
role of this receptor/ligand system in the
regulation of lymphatic vessels.
I. Production of antibodies for lymphatic
endothelial cells
Relatively little is known about the role of
lymphatic vessels in human pathological
conditions. One explanation for this has been
the lack of specific markers for lymphatic
endothelia leading to difficulties in the
recognition of these vessels. We produced
monoclonal antibodies against human VEGFR-3
in order to stain the lymphatic endothelial
cells in human tissue samples and to study the
lymphatic vessels in physiological and
pathological conditions in more detail.
II. Biological function of VEGFR-3
Gene deletion studies for two other receptors
in the VEGF family of growth factors, VEGFR-1
and VEGFR-2, showed embryonic lethal
phenotype due to defective blood vessel
development. Previous descriptive studies had
shown that VEGFR-3 is expressed in the
developing blood vessels in embryos before
lymphatic vessels are formed, but  its  role   in
early blood vessel development and adult
lymphatic vessels was not known. We created
mice lacking a functional gene encoding
VEGFR-3 in order to find out its biological
role.
III. Overexpression of ligands of VEGFR-3 in
transgenic mice
It was known that VEGF-C is able to stimulate
both angiogenesis and lymphangiogenesis, but
since this growth factor binds both VEGFR-2
and VEGFR-3 it was not clear which receptor
mediates the lymphangiogenic signals. VEGF-D
was shown to induce angiogenesis, but its
lymphangiogenic properties were not known.
To answer these questions, we overexpressed
mutant form of VEGF-C, which only binds to
VEGFR-3 (VEGF-C156S) and VEGF-D in the skin
of transgenic mice.
IV. VEGF-C in tumor development
Increased expression of VEGF-C in primary
tumors had been shown to correlate with
dissemination of tumor cells to regional lymph
nodes. However, the direct role for VEGF-C in
tumor lymphangiogenesis and metastasis was
not known. In order to answer this question,
we studied the role of VEGF-C in
tumorigenesis in transgenic mice, which had
overexpression of VEGF-C during pancreatic β-
cell tumor development.
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Materials and Methods
Production of monoclonal antibodies (I)
The extracellular part of the VEGFR-3 protein
was produced in a baculovirus expression
system and recombinant protein was purified
from the culture medium of the infected cells.
This protein was used for the immunization of
mice by intraperitoneal injection. After
sacrificing the mice the splenic lymphoid cells
were fused with plasmocytoma cells for the
production of antibodies. The clones were
tested by flow cytometry and purified from
hybridoma ascites fluid. One clone,
designated 9D9 was found to stably secrete a
monoclonal antibody. The specificity of this
antibody for VEGFR-3 was confirmed by FACS
(fluorescent activated cell sorting),
immunoprecipitation and Western blotting
analyses. The antibodies were used for
immunohistochemistry of human lymph node,
lymphoma, breast cancer and Kaposi’s
sarcoma samples.
VEGFR-3 gene deletion in mice (II)
Mice lacking a functional VEGFR-3 gene
(VEGFR-3-LacZ) were generated by
homologous recombination. In the gene
deletion construct the bacterial β -
galactosidase gene (LacZ) replaces the first
coding exon of the VEGFR-3 gene, leaving the
LacZ-marker gene under the transcriptional
regulatory sequences of VEGFR-3. Gene
targeting was confirmed by Southern blot
analysis. The product of this marker gene,
which mimics the expression of endogenous
VEGFR-3, can be visualized by the β -
galactosidase staining allowing the spatial and
temporal monitoring of the VEGFR-3 gene
expression in these mice.
Overexpression of VEGF-C and VEGF-D in
mice (III, IV)
Two different promoters were used to
overexpress VEGF-C or VEGF-D in transgenic
mice. Human keratin-14 (K14) promoter was
used to direct the expression of full-length
human VEGF-C156S (89), VEGF-C or VEGF-D to
the basal cells of the epidermis in the skin of
transgenic mice. Rat insulin promoter (Rip)
was used to target the human VEGF-C
expression to pancreatic β-cells. Transgenic
mice were generated by microinjection of
transgenic DNA constructs into the pronucleus
of fertilized oocytes. The resulting mouse
lines were analysed for the expression of the
transgene by Northern and Southern blotting.
The biological consequences of the
overexpression of these growth factors were
studied in skin or pancreatic tissue samples.
Rip-VEGF-C transgenic mice were further
crossed with the Rip1Tag2 (SV40 Tag
oncogene) transgenic line, which develop
pancreatic β-cell tumors, in order to study the
role of VEGF-C in tumorigenesis.
Visualization of blood and lymphatic vessels
(I-IV)
Several methods were used to visualize the
lymphatic vessels in human and mouse tissues.
Antibodies against VEGFR-3 (mouse-anti-
human MoAb clone 9D9 or rat-anti-mouse
MoAb from Dr. Hajime Kubo) or LYVE-1
(rabbit-anti-mouse PoAb from Dr. D. Jackson)
were used for the immunohistochemical
staining of lymphatic vessels. Blood vessels
were stained for antibodies against vWF
(mouse-anti-human PoAb, Dako), CD31
(mouse-anti human MoAb, Dako and rat-anti-
mouse PECAM1, Pharmingen), Pal-e (mouse
anti-human MoAb, Pharmingen) and MECA-32
(from Dr. Hallman). Also antibodies against
Tie2 (mouse-anti-human, from Dr. Toshio
Suda), for high endothelial venules (Heca 452
from Dr. Sirpa Jalkanen and Slex CD15s from
Pharmingen), VEGFR-2 (from Dr. Hajime
Kubo), VEGF-C (rabbit-anti-human 882 (91)),
and VEGF-D (biotinylated goat-anti-mouse,
R&D Systems) was used.
Heterozygous VEGFR-3-lacZ mice were used
for the visualization of lymphatic vessels in
whole mounts of tissue. After β-galactoside
staining VEGFR-3 expression sites can be seen
in blue. These mutant mice were further
crossed with K14-VEGF-C156S and K14-VEGF-D
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mice to allow the comparison of the lymphatic
vessels after transgenic overexpression of
these growth factors. Fluorescent dextran
(Sigma) and ferritin (Sigma) macromolecules
as well as Evans blue dye (Sigma) were used
for the intradermal injections in order to
visualize the intake and transport capacities
of the lymphatic vessels.  Intravenous
injections of L. esculentum lectin (Vector)
following the intracardial perfusion of the
fixative were used to visualize the blood
vessels in whole mounts of mouse tissue.
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Results and Discussion
I. Antibodies against VEGFR-3 stain
lymphatic vessels
Monoclonal antibodies produced against the
extracellular part of the VEGFR-3 protein
stained specifically the endothelial cells of
lymphatic vessels. By using these antibodies I
could visualize the lymphatic endothelial cells
for  the  f i r s t  t ime by  s ing le
immunohistochemical staining and a
comparison with the blood vessels was
possible. The lymphatic vessels were stained
in both physiological (lymph node and tonsil)
and pathological (lymphoma, breast cancer)
human tissue samples. Interestingly, the
spindle cells of the Kaposi’s sarcoma stained
positive for VEGFR-3, providing further
evidence for the origin of these cells from
lymphatic endothelial cells rather than from
the blood vascular endothelial cells. This was
recently confirmed by similar results obtained
by other group with antibodies against
podoplanin, another marker for lymphatic
endothelial cells (23, 92). The spindle cells of
Kaposi’s sarcoma have also been shown to
express VEGFR-2, Ang-2, Tie-1, and Tie-2 (24,
146, 175). The anti-VEGFR-3 antibodies
introduced in this study provide a useful tool
for the studies of lymphatic vessels in disease
and inflammatory processes.
In further studies by using these antibodies,
new information about VEGFR-3 expression
has been gained. In addition to lymphatic
endothelial cells, VEGFR-3 is seen in a subset
of capillary cells and the venous endothelium
in adults (147). The fenestrated capillary
endothelia of the endocrine organs express
VEGFR-3, implying that it may have a role in
the endothelial transport functions. VEGFR-3
is also seen in blood vascular endothelia at
sites of hematopoiesis or blood cell
trafficking, such as in the sinusoids of the
liver, spleen and bone marrow. Also some
nonendothelial expression of VEGFR-3 has
been observed in embryonic notochordal cells
and in the throphoblasts of the placenta (147,
200).
Upregulation of VEGFR-3 expression was seen
in the angiogenic blood vessels associated
with tumor growth (193). Conversely, no
upregulation of VEGFR-3 was seen in the
angiogenic vessels of a healing wound,
whereas transient invasion of VEGFR-3 positive
lymphatic vessels was seen to follow the
growth of blood vessels into the granulation
tissue (141). Suprisingly, VEGFR-3 was widely
expressed in the endothelial cells of benign
and malignant vascular tumors. VEGFR-3 may
thus have more complicated role in the
regulation of blood and lymphatic vessels that
my previous studies suggested. VEGFR-3 is
expressed in the embryonic arteries and veins
but in adults it is predominantly seen in
lymphatic endothelia.  However, it seems to
become upregulated in immature blood
vascular endothelial cells, such as in
proliferating vascular tumors or in tumor
angiogenic vessels. This is consistent with the
finding that VEGFR-3 is seen in the developing
blood vessels of embryos (44, 93). In addition
to visualization of lymphatic vessels in adult
physiological conditions the anti-VEGFR-3
antibodies can thus be used for the diagnostic
of malformations and tumors of both blood
and lymphatic vessels. The knowledge about
the regulation of lymphatic vessels has just
began to accumulate and further studies will
show whether the lymphangiogenesis is
differently regulated in various physiological
and pathological situations.
Recently, lymphatic endothelial cells were
isolated from cell cultures by these
monoclonal antibodies against VEGFR-3 (125).
The availability of lymphatic endothelial cells
now allows a more specific study of the
genetic and functional properties of these
cells and will help to uncover their
contribution to molecular pathogenesis where
the lymphatic vessels are involved. Freshly
isolated lymphatic endothelial cells from
malignant and normal tissues would be useful
for example in understanding the interactions
of stromal lymphatic endothelial cells and
tumor cells in for example breast carcinomas.
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Isolated lymphatic endothelial cells along with
their growth factors could also prove useful in
the reconstitution of a functional lymphatic
network in the axillar region after radical
surgery for advanced breast carcinoma.
II. VEGFR-3 in embryonic development
studied by gene disruption strategy
I studied the biological role of VEGFR-3 in
relation to the vascular development in
VEGFR-3 gene deficient mice. Mice
heterozygous for VEGFR-3 were healthy and
fertile and the development of the blood and
lymphatic vessels appeared normal. However,
no mice lacking the both alleles of VEGFR-3
were born. The homozygous mutant embryos
failed to thrive and died in utero around
midgestation. Analysis of the homozygote
embryos revealed cardiovascular failure with
deficient blood vessel formation. VEGFR-3 was
thus shown to have an important role in
embryonic blood vessel development before
the lymphatic vessels start to develop. In
embryos deficient for VEGFR-3, yolk sac
lacked major blood vessels and the large
vessels of the embryo, anterior cardinal vein
and dorsal aorta, were rudimentary. In further
studies, VEGFR-3 deficient embryos were
found to suffer from anemia (75), probably
due to defects in the vitelline vessels of the
yolk sac impairing the yolk sac hematopoiesis.
In the head region the vascular plexus failed
to undergo remodelling. On the other hand,
no major defects occurred in the
differentiation of the endothelial cells or in
the formation of the primary vascular
networks by vasculogenesis or sprouting
angiogenesis. As the lack of both alleles of
VEGFR-3 was lethal at midgestation, the
effects of VEGFR-3 in the development of the
lymphatic vasculature remain to be seen.
However, the normally developing, healthy
heterozygote embryos and mice can be used
to visualize the lymphatic vessels during
development and in physiological and
pathological processes.
The majority of blood vessel endothelial cell
populations around midgestation are positive
for both VEGFR-2 and VEGFR-3, suggesting
that these receptors play essential roles in
angiogenesis (75). VEGFR-1 is also seen in the
developing vasculature at this stage (61).
Endothelial cells are apparently activated by
both VEGF and VEGF-C at this stage but it is
not known whether these receptors transduce
similar signals. The VEGF/VEGFR-2 system
appears to be responsible for most of the
growth signals for vascular endothelial cells,
but it has also been proposed that VEGF-C
induces proliferation and differentiation of
embryonic vascular endothelial cells through
VEGFR-2. VEGF-C signalling through VEGFR-2
and VEGFR-3 may thus have distinct roles in
embryogenic vasculogenesis (75). In addition,
in VEGF deficient mice some endothelial cells
survive and this may be due to VEGF-C.
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Figure 6. VEGFR-3 expression during embryonic development. β-galactosidase
activity reveals VEGFR-3 expression in mice embryos deficient for VEGFR-3 (arrows
in A-C). VEGFR-3 is essential for the development of blood vessels at midgestation
(A), but at later stages its expression is seen in the developing lymphatic vessels
(B). In older embryos (C) as well as in adults the VEGFR-3 expression is mainly
seen in the lymphatic vessels and the expression in the blood vessels is
downregulated (arrowhead in C).
III. Lymphatic hyperplasia in the skin of
transgenic mice overexpressing VEGF-C and
VEGF-D
In addition to VEGFR-3, VEGF-C also binds
VEGFR-2, which is expressed in both blood and
lymphatic endothelia. Therefore it was not
clear which receptors mediates the
lymphangiogenic effects of VEGF-C. VEGF-D,
which binds to the same receptors, was
reported to induce angiogenesis, but its role
in lymphangiogenic processes was not known.
In order to study the lymphangiogenic
signalling pathway more specifically, we
created transgenic mice overexpressing a
VEGFR-3 specific mutant of VEGF-C (VEGF-
C156S (89)) or VEGF-D in epidermal
keratinocytes of the skin. Both transgenes
were seen to be able to induce hyperplasia of
lymphatic vessels by both proliferation of the
endothelial cells and also by the growth of
new lymphatic sprouts. On the other hand,
the blood vessel architecture was not affected
in these mice, demonstrating that stimulation
of the VEGFR-3 is sufficient specifically to
induce lymphangiogenesis in vivo. These
transgenic models for lymphatic hyperplasia
now allow studies of the biology of lymphatic
vessels in   pathological   conditions     such as
wound healing, tumor progression and
metastasis.
Recently, mice expressing the soluble ligand-
binding part of the VEGFR-3 in the skin
keratinocytes were generated (123). This
soluble receptor protein inhibits the binding of
endogenous VEGF-C and VEGF-D to the
membrane bound receptor and thus
neutralizes the activity of these growth
factors. Interestingly, the mice were devoid of
dermal lymphatics due to the inhibition of skin
lymphangiogenesis and subsequent regression
of existing lymphatic vessels during later
embryonic development. This indicates that
continuous signalling by VEGFR-3 is needed for
the maintenance of the lymphatic vasculature
and that soluble VEGFR-3 could be used as a
specific inhibitor of lymphangiogenesis. The
effect was specific for the lymphatic vessels,
as the blood vasculature remained normal.
However, the lymphatic vessels began to
regrow after a few weeks postnatally even
thought transgene encoded protein could be
detected in the serum. It is thus possible that
lymphatic vessels undergo maturation or
otherwise become resistant to loss of VEGFR-3
ligands after early postnatal development.
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The exact roles of VEGF-C and VEGF-D during
embryonic vascular development are still
unknown due to a lack of gene deletion
studies. Their receptors VEGFR-2 and VEGFR-3
can be expressed variably in both blood and
lymphatic endothelia and proteolytic
processing regulates their binding affinity to
the receptors.  Therefore, VEGF-C and VEGF-D
may regulate the responses of lymphatic
vessels in adults, but they may also have
important roles in physiological and
pathological angiogenesis in various
conditions. VEGF-C and VEGF-D may also
affect the fluid dynamics of lymphatic vessels,
and be involved in the formation of valves and
recruitment of smooth muscle cells to the
developing lymphatic collecting vessels.
Unpublished data indicates that VEGF-C and
VEGF-D can heterodimerize (Michael Jeltsch
personal communication), as has been
reported for PlGF and VEGF as well as VEGF-B
and VEGF (27, 137). This may make their
biological properties even more diverse.
IV. A genetic model of tumor metastasis
in transgenic mice
VEGF-C overexpression was targeted to the β-
cells of the pancreatic Langerhans islets in
order to study the biological role of the VEGF-
C in another organ system.  An extensive
network of lymphangiogenic vessels was seen
around the pancreatic islets in the transgenic
mice, whereas no such vessels were seen in
the control mice.  The transgenic mice where
further crossed with Rip1Tag2 mice, which
develop pancreatic β-cell tumors, in order to
study VEGF-C during carcinogenesis. These
tumors display morphological features typical
of human insulinomas and they are capable of
local invasion, but do not metastasize. Double
transgenic tumors retained VEGF-C expression
during the tumor progression. Interestingly,
the tumors were surrounded by wide
lymphatic channels, which contained
aggregates of tumor cells. In 37% of the
doubletransgenic mice, metastatic tumor cells
were observed in the regional mesenteric
lymph nodes, whereas no tumor cells were
observed in the lymphatic vessels or lymph
nodes of the control mice. These findings
identify VEGF-C-induced lymphangiogenesis as
a critical mediator of tumor metastasis.
However, no increase in angiogenesis by
VEGF-C was observed in these mice.
Similarly, human breast cancer cells
expressing ectopic VEGF-C was reported to
induce lymphangiogenesis in orthotopically
implanted tumors (97, 176). Increased
spreading of the cells to the regional lymph
nodes was observed and the degree of tumor
lymphangiogenesis was highly correlated with
the distant metastases. Also, VEGF-C induced
lymphangiogenesis was inhibited by adenoviral
treatment with soluble VEGFR-3 receptor (97)
but no differences in tumor growth or
angiogenesis was observed.
Although it seems evident that both VEGF-C
and VEGF-D can induce the growth of new
lymphatic vessels, several questions remain
u n a n s w e r e d  r e g a r d i n g  t u m o r
lymphangiogenesis and metastasis. For
example, it is not known whether it is
sufficient for preexisting lymphatic vessels to
expand by circumferential growth, or whether
new vessels are required for the enhancement
of the metastatic process. On the other hand,
lymphatic vessels may either actively
penetrate into existing tumors or become
trapped in between expanding tumor foci. The
intratumoral lymphatic vessels observed are
usually collapsed due to the high interstitial
pressure in solid tumors, impairing their
transport capacity. Also, as in angiogenesis,
lymphangiogenesis may occur by several
mechanisms and different regulatory factors
may be involved.
Activation of lymphatic endothelial cells by
tumor cell secreted factors may promote the
interaction of tumor cells with lymphatic
endothelial cells, and thereby facilitate tumor
cell entry into the lymphatics. In spite of the
increased metastatic tendency of VEGF-C
overexpressing tumor cells, metastases were
only seen in about one third of the tumor
bearing mice. Overall, on the basis of studies
in which VEGF-C or VEGF-D has been
overexpressed in tumors, one could suggest
that there are additional, rate-limiting steps
in the metastatic process. The simpliest
explanation for the metastasis-enhancing
effects of VEGF-C and VEGF-D is that they
eliminate one rate-limiting step by increasing
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the surface area between invading tumor
cells, which are in contact with the
hyperplastic lymphatic endothelium. However,
they could also facilitate metastasis by
increasing vascular permeability, by changing
the adhesive properties, or cytokine or
chemokine expression patterns of the
lymphatic endothelium. VEGF-C and VEGF-D
secreted by the tumor cells could also have an
important effect on the tumor interstitial
pressure. Both can increase vascular leakage,
but not as efficiently as VEGF, and a parallel
increase in lymphangiogenesis could alleviate
this effect. The increased interstitial pressure
could be a major determinant of tumor cell
seeding into the blood vascular and lymphatic
circulation, especially as recent studies have
shown that a proportion of the lumen of tumor
blood vessels themselves consists of tumor
cells (35, 78).
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Conclusions
The development and regulation of
endothelial cells requires many growth factors
orchestrating in a carefully co-ordinated
manner. Blood and lymphatic vessels are
formed in parallel during embryonic
development but both vessel types are
maintained in a rather quiescent stage in
adults, being activated only in sites of new
growth of the tissue. The role of lymphatic
vessels in various diseases has not been
studied much, but the recent discoveries of
specific molecules involved in the biology of
lymphatic vessels now allows more extensive
studies of these vessels. Similarities between
the regulation of blood and lymphatic vessels
have been observed and these two vessel
systems seem to work in a tightly regulated
manner. Lymphangiogenesis may occur at sites
of angiogenesis, either following the growth of
blood vessels, like in wound healing, or acting
independently as has been seen in
experimental tumor models. The findings
made so far will be helpful in diagnosis of
certain vascular tumors, designing specific
treatments for lymphedema and attempts to
regulate the metastatic spread of tumor cells
via lymphatic vessels. In addition, the
isolation and culturing of lymphatic
endothelial cells offers additional tools for the
study of the molecular characteristics of these
cells.
The growth factors VEGF-C and VEGF-D and
their receptor VEGFR-3 are the first molecules
found to regulate the lymphatic endothelial
cells. This study presents further data on the
biological role of VEGFR-3 during embryonic
development as well as in adult physiological
and pathological conditions. The experimental
studies presented here show the potential of
the growth factors VEGF-C and VEGF-D to
induce the growth of lymphatic vessels. The
challenge for future studies will be the use of
these molecules in therapeutic purposes, or
for the inhibition of VEGFR-3 signalling to
prevent the metastatic spread of tumors via
lymphatic vessels.
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